Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

Three months sep­a­rat­ed from a dis­ap­point­ing read­out of its Covid-19 vac­cine, Icosavax is back with what it calls pos­i­tive topline da­ta for a dif­fer­ent VLP vac­cine can­di­date — al­though in­vestors aren’t im­pressed.

IVX-121, a vac­cine can­di­date for res­pi­ra­to­ry syn­cy­tial virus (RSV), ap­peared to gen­er­ate “ro­bust” im­mune re­spons­es among both young and old­er adults, as mea­sured by neu­tral­iz­ing an­ti­bod­ies, and ap­peared gen­er­al­ly well-tol­er­at­ed, Icosavax re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER